Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
DX 8951
Known as:
DX-8951
National Institutes of Health
Create Alert
Related topics
Related topics
1 relation
Broader (1)
exatecan
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors
Moritz N. Wente
,
J. Kleeff
,
+4 authors
H. Friess
Investigational New Drugs
2005
Corpus ID: 1760800
Background: DE-310 is composed of the topoisomerase-I-inhibitor DX-8951 (exatecan) and a biodegradable macromolecular carrier…
Expand
2005
2005
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer
J. Ajani
,
C. Takimoto
,
+7 authors
R. Jager
Investigational New Drugs
2005
Corpus ID: 7414878
Purpose: To determine the anti-tumor activity DX-8951f when administered as a 30-minute infusion daily for 5 days every 3 weeks…
Expand
2004
2004
A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951
Y. Ochi
,
Y. Shiose
,
H. Kuga
,
E. Kumazawa
Cancer Chemotherapy and Pharmacology
2004
Corpus ID: 42366266
DE-310, a new macromolecular prodrug, was designed to enhance the pharmacological profiles of a novel camptothecin analog (DX…
Expand
2002
2002
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
F. Giles
,
J. Cortes
,
+5 authors
H. Kantarjian
Clinical cancer research : an official journal of…
2002
Corpus ID: 7507154
PURPOSE DX-8951f is a novel hexacyclic camptothecin-analogue topoisomerase I inhibitor with both in vitro antileukemic activity…
Expand
2001
2001
Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.
T. Oguma
,
T. Konno
,
A. Inaba
,
M. Nakaoka
Biomedical chromatography : BMC
2001
Corpus ID: 25063707
A new liquid chromatographic/mass spectrometric assay has been developed for the determination of DX-8951, a new anti-tumor drug…
Expand
2001
2001
High-Performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (exatecan), in mouse plasma.
T. Oguma
,
M. Yamada
,
T. Konno
,
K. Inukai
,
M. Nakaoka
Biological & pharmaceutical bulletin
2001
Corpus ID: 45573023
A sensitive high-performance liquid chromatographic (HPLC) method has been developed and validated for the determination of…
Expand
2000
2000
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
E. Rowinsky
,
T. R. Johnson
,
+10 authors
R. D. De Jager
Journal of clinical oncology : official journal…
2000
Corpus ID: 30525792
PURPOSE To assess the feasibility of administering DX-8951f (exatecan mesylate), a water-soluble, camptothecin analog, as a 30…
Expand
2000
2000
Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma…
T. Oguma
,
Y. Ohshima
,
M. Nakaoka
Journal of chromatography. B, Biomedical sciences…
2000
Corpus ID: 40214402
A sensitive quantitation of the lactone form and the lactone plus hydroxy-acid forms of DX-8951, a camptothecin derivative, in…
Expand
Review
2000
Review
2000
DX‐8951f: Summary of Phase I Clinical Trials
R. Jager
,
P. Cheverton
,
+5 authors
M. Suzuki
Annals of the New York Academy of Sciences
2000
Corpus ID: 40816714
Abstract: Exatecan mesylate (DX‐8951f) is a new hexacyclic camptothecin analogue with favorable attributes compared to topotecan…
Expand
1997
1997
Antitumor Effect of DX‐8951, a Novel Camptothecin Analog, on Human Pancreatic Tumor Cells and Their CPT‐11‐resistant Variants Cultured in vitro and Xenografted into Nude Mice
S. Takiguchi
,
E. Kumazawa
,
T. Shimazoe
,
A. Tohgo
,
A. Kono
Japanese journal of cancer research : Gann
1997
Corpus ID: 13718482
DX‐8951 is a novel water‐soluble derivative of camptothecin. We evaluated the effects of DX‐8951 on the growth of several…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE